Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

Background Vaccination of children and young people against SARS-CoV-2 is recommended
in some countries. Scarce data have been published on immune responses induced by …

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine,
has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (…

Both infection and vaccination, alone or in combination, generate antibody and T cell
responses against SARS-CoV-2. However, the maintenance of such responses – and hence …

Background This was the first study to investigate the reactogenicity and immunogenicity of
heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. …

Background: Vaccination of children and young people against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is recommended in some countries. There are few data …